In the last trading session, 1.01 million shares of the Candel Therapeutics Inc (NASDAQ:CADL) were traded, and its beta was -1.23. Most recently the company’s share price was $6.61, and it changed around -$0.05 or -0.90% from the last close, which brings the market valuation of the company to $293.76M. CADL currently trades at a discount to its 52-week high of $14.60, offering almost -120.88% off that amount. The share price’s 52-week low was $1.16, which indicates that the current value has risen by an impressive 82.45% since then. We note from Candel Therapeutics Inc’s average daily trading volume that its 10-day average is 1.68 million shares, with the 3-month average coming to 3.72 million.
Candel Therapeutics Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended CADL as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Candel Therapeutics Inc is expected to report earnings per share of 0 for the current quarter.
Candel Therapeutics Inc (NASDAQ:CADL) trade information
Instantly CADL has showed a red trend with a performance of -0.90% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 8.08 on recent trading dayincreased the stock’s daily price by 18.19%. The company’s shares are currently down -23.91% year-to-date, but still down -14.99% over the last five days. On the other hand, Candel Therapeutics Inc (NASDAQ:CADL) is 0.08% up in the 30-day period. We can see from the shorts that 1.78 million shares have been sold at a short interest cover period of 7.72 day(s).
Candel Therapeutics Inc (CADL) estimates and forecasts
Candel Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 9.90 percent over the past six months and at a -21.37% annual growth rate that is well below the industry average of 16.50%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -46.75%.
CADL Dividends
Candel Therapeutics Inc’s next quarterly earnings report is expected to be released in February.
Candel Therapeutics Inc (NASDAQ:CADL)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 30.39% of Candel Therapeutics Inc shares, and 22.53% of them are in the hands of institutional investors. The stock currently has a share float of 32.37%. Candel Therapeutics Inc stock is held by 74.0 institutions, with NORTHPOND VENTURES, LLC being the largest institutional investor. By 2024-06-30, it held 6.628% of the shares, which is about 1.94 million shares worth $12.0 million.
BLACKROCK INC., with 2.819% or 0.82 million shares worth $5.1 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Oct 31, 2024 . The former held 511.78 shares worth $3.38 million, making up 1.58% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 453.81 shares worth around $3.0 million, which represents about 1.40% of the total shares outstanding.
